Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR001 in advanced triple-negative breast cancer
NCT07208149Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MR001 in triple-negative breast cancer (TNBC). Started Jan 2026; status: recruiting.
02
Drugs
MR001
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07208149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208149.